First‐line combination chemotherapy with etoposide, ifosfamide and cisplatin for the treatment of disseminated germ cell cancer: Efficacy and feasibility in current clinical practice
Author:
Affiliation:
1. Department of Urology Cancer Institute Hospital Japanese Foundation for Cancer Research TokyoJapan
2. Department of Urology Tokyo Medical and Dental University Graduate School Tokyo Japan
Funder
Smoking Research Foundation
Publisher
Wiley
Subject
Urology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14604
Reference28 articles.
1. Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer
2. Clinical characteristics and oncological outcomes of testicular cancer patients registered in 2005 and 2008: The first large-scale study from the Cancer Registration Committee of the Japanese Urological Association
3. Guidelines on Testicular Cancer: 2015 Update
4. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
5. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Editorial Comment to Plasma circulating tumor DNA profiling in patients with chemo‐refractory germ cell tumors;International Journal of Urology;2023-02-23
2. Trends of incidence and age in adults with testicular germ cell tumors: a two-decade multicenter retrospective study;Translational Andrology and Urology;2023-02
3. Effects of primary granulocyte‑colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors;Oncology Letters;2022-07-13
4. Cisplatin/etoposide/ifosfamide;Reactions Weekly;2022-06
5. From a Chemotherapeutic Drug to a High-Performance Nanocatalyst: A Fast Colorimetric Test for Cisplatin Detection at ppb Level;Biosensors;2022-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3